HOLX Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 19.67% compared to Hologic's net margin of 32.59%. Hologic's return on equity of 15.28% beat Eli Lilly and's return on equity of 80.24%.

Hologic has a consensus price target of $76.03, signalling upside risk potential of 34.56%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.89 which suggests that it could grow by 37.28%. Given that Eli Lilly and has higher upside potential than Hologic, analysts believe Eli Lilly and is more attractive than Hologic.

Hologic has a beta of 0.825, which suggesting that the stock is 17.493% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Hologic pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hologic quarterly revenues are $1B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Hologic's net income of $201M is lower than Eli Lilly and's net income of $4.4B. Notably, Hologic's price-to-earnings ratio is 17.82x while Eli Lilly and's PE ratio is 62.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.29x versus 14.75x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 19.67% compared to Hologic's net margin of 23.96%. Hologic's return on equity of 15.28% beat Merck &'s return on equity of 40.25%.

Hologic has a consensus price target of $76.03, signalling upside risk potential of 34.56%. On the other hand Merck & has an analysts' consensus of $110.89 which suggests that it could grow by 45.02%. Given that Merck & has higher upside potential than Hologic, analysts believe Merck & is more attractive than Hologic.

Hologic has a beta of 0.825, which suggesting that the stock is 17.493% less volatile than S&P 500. In comparison Merck & has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.879%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.13% to investors and pays a quarterly dividend of $0.81 per share. Hologic pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hologic quarterly revenues are $1B, which are smaller than Merck & quarterly revenues of $15.6B. Hologic's net income of $201M is lower than Merck &'s net income of $3.7B. Notably, Hologic's price-to-earnings ratio is 17.82x while Merck &'s PE ratio is 11.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.29x versus 3.03x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 19.67% compared to Hologic's net margin of 2.31%. Hologic's return on equity of 15.28% beat Pfizer's return on equity of 8.91%.

Hologic has a consensus price target of $76.03, signalling upside risk potential of 34.56%. On the other hand Pfizer has an analysts' consensus of $30.16 which suggests that it could grow by 38.15%. Given that Pfizer has higher upside potential than Hologic, analysts believe Pfizer is more attractive than Hologic.

Hologic has a beta of 0.825, which suggesting that the stock is 17.493% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.67% to investors and pays a quarterly dividend of $0.43 per share. Hologic pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Hologic quarterly revenues are $1B, which are smaller than Pfizer quarterly revenues of $17.8B. Hologic's net income of $201M is lower than Pfizer's net income of $410M. Notably, Hologic's price-to-earnings ratio is 17.82x while Pfizer's PE ratio is 15.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.29x versus 1.97x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 19.67% compared to Hologic's net margin of 24.22%. Hologic's return on equity of 15.28% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Hologic has a consensus price target of $76.03, signalling upside risk potential of 34.56%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $891.50 which suggests that it could grow by 62.59%. Given that Regeneron Pharmaceuticals has higher upside potential than Hologic, analysts believe Regeneron Pharmaceuticals is more attractive than Hologic.

Hologic has a beta of 0.825, which suggesting that the stock is 17.493% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.16% to investors and pays a quarterly dividend of $0.88 per share. Hologic pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $1B, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Hologic's net income of $201M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Hologic's price-to-earnings ratio is 17.82x while Regeneron Pharmaceuticals's PE ratio is 14.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.29x versus 4.45x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.